Atlantic Equities said in its upgrade of the stock that the "negative price action" was "overdone."'s past performance during recessions, we are reducing 2021/2022 EPS from $5.91/$6.54 to $4.21/$4.61 respectively as we assume coronavirus issues ease towards the year end but are replaced by a recession.
"We view Major Pharma as relatively attractive given its defensive qualities. Companies continue to have solid financial prospects despite some impacts due to COVID-19, offer attractive dividend yields, and can capitalize on lower biotech industry valuations & enhance pipelines via M&A. Upgrading
Pro Bet on the bottom.... you'll be walking around town with bottoms, off
Pro Short short short
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: politico - 🏆 381. / 59 続きを読む »